Primary spinal glioblastoma multiforme. Single center experience and literature review

• Published in: Interdisciplinary neurosurgery : Advanced techniques and case management Vol. 24; p. 101109
• Main Authors: Jokovic, Milos, Somma, Teresa, Ilic, Rosanda, Guizzardi, Giulia, Stanimirovic, Aleksandar, Raicevic, Savo, Milicevic, Mihajlo, Grujicic, Danica, Solari, Domenico
• Format: Journal Article
• Language: English
• Published: Elsevier B.V 01-06-2021; Elsevier
• Subjects: Glioblastoma multiforme; Primary spinal GBM; Spine surgery; TMZ; RT; OS; GTR; MRI; IOM; Spine surgery; EOR; SSEP; Glioblastoma multiforme; CHT; GBM; Primary spinal GBM; MEP; D-wave; PFS
• ISSN: 2214-7519; 2214-7519
• DOI: 10.1016/j.inat.2021.101109

Spinal glioblastomas represent a rare entity accounting for ca 1–3% of all intramedullary tumors; data about survival, prognostic factors and therapeutic protocols are quite poor. Even with an aggressive multimodal management the spinal glioblastoma patients’ survival remains poor, with rapid progression of the disease. This study reports our experience with the management of the primary intramedullary glioblastomas, also in regard to the current literature data.
We retrospectively analyzed the medical records of 5 patients treated at the Department for Neuro-oncology and Spine Surgery of the Clinical Center of Belgrade, Serbia, between January 2007 and December 2016 for a primary intramedullary glioblastoma. Demographic characteristics, pre-operative data and post-operative results were then compared with previous literature regarding spinal GBMs and attempt to identify potential prognostic factors.
Gross total resection was achieved in two patients, while a subtotal resection was performed in the latter 3 cases; as per protocol, all patients underwent to surgery, followed by radio and chemotherapy. There were no intraoperative complications and no patients developed a new postoperative neurological defect; the median overall survival was 6 months. Progression or recurrence of disease was noted in all patients at the 3-months follow-up, despite the adjuvant treatments.
To the date, there is a lack of consensus on specific management of spinal glioblastomas: the extent of resection can play an important role, but it appears to be not preeminent. A shorter interval between symptoms onset and treatment and a smaller extension of the tumor seem to be correlated with better outcomes and a longer overall survival. However, there is not an adjunctive viable standardized postoperative therapy yet, which results in concrete and persistent improvement of overall survival and progression free survival.